Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

@article{Cuzick2012PrognosticVO,
  title={Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort},
  author={J. Cuzick and D. Berney and G. Fisher and D. Mesher and H. M{\o}ller and J. Reid and M. Perry and J. Park and A. Younus and A. Gutin and C. Foster and P. Scardino and J. Lanchbury and S. Stone},
  journal={British Journal of Cancer},
  year={2012},
  volume={106},
  pages={1095 - 1099}
}
Background:The natural history of prostate cancer is highly variable and it is difficult to predict. We showed previously that a cell cycle progression (CCP) score was a robust predictor of outcome in a conservatively managed cohort diagnosed by transurethral resection of the prostate. A greater need is to predict outcome in patients diagnosed by needle biopsy.Methods:Total RNA was extracted from paraffin specimens. A CCP score was calculated from expression levels of 31 genes. Clinical… Expand

Paper Mentions

Observational Clinical Trial
The Trans-Atlantic Prostate Group (TAPG) was established to examine the hypothesis that through a detailed retrospective analysis of outcome in a group of men with clinically… Expand
ConditionsProstate Cancer
Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort
TLDR
The CCP score provides significant pretreatment prognostic information that cannot be provided by clinical variables and is useful for determining which patients can be safely managed conservatively, avoiding radical treatment. Expand
Analytical Validation of a Cell Cycle Progression Signature Used as a Prognostic Marker in Prostate Cancer
TLDR
These studies indicate that this prognostic gene signature is robust and reproducible, and is analytically validated for use on FFPE prostate biopsy radical prostatectomy samples. Expand
Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.
TLDR
If validated in a larger cohort, CCP score could identify high-risk men undergoing EBRT who may need more aggressive therapy and provided greater prognostic information than was available with clinical parameters. Expand
Re: Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
TLDR
The CCP score was validated to have significant prognostic accuracy after controlling for all available clinical and pathologic data, and may improve accuracy of risk stratification for men with clinically localized prostate cancer, including those with low-risk disease. Expand
Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
TLDR
The CCP score was validated to have significant prognostic accuracy after controlling for all available clinical and pathologic data, and may improve accuracy of risk stratification for men with clinically localized prostate cancer, including those with low-risk disease. Expand
Validation of a panel of cell-cycle progression genes for improved risk stratification in a contemporary radical prostatectomy cohort.
TLDR
In a contemporary post-RP cohort, the CCP score was validated to have significant prognostic accuracy even when controlling for clinical and pathologic data and has potential to substantially improve accuracy of risk-stratification. Expand
Cell cycle progression score improves risk stratification in prostate cancer patients with adverse pathology after radical prostatectomy
TLDR
Insight is provided into the role the CCP score plays in risk stratification of this cohort and in determining candidacy for deferred secondary treatment and can help identifying patients at lower risk of disease recurrence who could benefit from a wait-and-see policy. Expand
Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort
TLDR
The IHC Ki-67 scoring on prostate needle biopsies is practicable and yielded significant prognostic information, but it was less informative than in the previous TURP cohort where tumour samples were larger and more comprehensive, but in more contemporary cohorts with larger numbers ofBiopsies per patient, Ki- 67 may prove a more powerful biomarker. Expand
Prognostic value of a cell cycle progression score for men with prostate cancer.
  • J. Cuzick
  • Medicine
  • Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
  • 2014
TLDR
Data provide strong event to support use of the CCP score to help guide clinical management and a unit change in CCP score was associated with an approximate doubling of risk of an event. Expand
Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy.
  • I. H. López, D. Parada, +8 authors M. Arenas
  • Medicine
  • Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
  • 2017
TLDR
High Ki-67 significantly predicted outcome and provided prognostic information and CCP score may improve accuracy stratification, but did not provide prognostic correlation of CCP and DSM. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.
TLDR
There is strong evidence that the CCP score is a robust prognostic marker, which, after additional validation, could have an essential role in determining the appropriate treatment for patients with prostate cancer. Expand
Long-term outcome among men with conservatively treated localised prostate cancer
TLDR
A model using Gleason score and PSA level identified three subgroups comprising 17, 50, and 33% of the cohort with a 10-year prostate cancer specific mortality of <10, 10–30, and >30%, respectively, which is a substantial improvement on previous ones using only Gleason scored, but better markers are needed to predict survival more accurately in the intermediate group of patients. Expand
Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies
TLDR
The Gleason grading system is a powerful tool to prognosticate and aid in the treatment of men with prostate cancer, but there are significant deficiencies in the practice of this grading system. Expand
The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study.
OBJECTIVES The prevalence of incidental prostatic adenocarcinoma (PCa) and its precursor, high grade intraepithelial neoplasia (HGPIN) in an autopsy series from Hungarians (Central EuropeanExpand
Construction of tissue microarrays from prostate needle biopsy specimens
TLDR
Serial sectioning of the TMAs, called ‘Checkerboard TMAs’, facilitated expression analysis of multiple proteins using IHC markers, and 100% of the analysed biopsies within the TMA both preserved their antigenicity and maintained their morphology. Expand
Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force
TLDR
Prostate-specific antigen-based screening results in small or no reduction in prostate cancer-specific mortality and is associated with harms related to subsequent evaluation and treatments, some of which may be unnecessary. Expand
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
TLDR
The results suggest that the majority of screen-detected cancers diagnosed between 1988 and 1998 would have presented clinically and that only a minority of cases found at autopsy would have been detected by PSA testing. Expand
High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases.
TLDR
HGPIN was encountered in 0, 5, 10, 41 and 63% of men in the 3rd, 4th, 5th and 7th decades, respectively, and corresponding figures for invasive carcinoma were 2, 29, 32, 55, and 64% respectively. Expand
Changes in prostate cancer incidence and treatment in USA
TLDR
Increases in rates of prostate cancer incidence and prostate surgery have occurred in the United States without clear evidence that screening and prostectomy are effective in reducing mortality, particularly among older men, who appear least likely to benefit from early detection and surgery of occult prostate cancer. Expand
Latent carcinoma of prostate at autopsy in seven areas. Collaborative study organized by the International Agency for Research on Cancer, Lyons, France
TLDR
Two Chinese populations showed a low frequency of latent carcinoma in comparison with western Europeans in Sweden and the Federal Republic of Germany and negroes from Jamaica; an intermediate position was found for Israelis and black Ugandans. Expand
...
1
2
3
...